Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 and Niraparib in Metastatic Breast Cancer
NCT04508803Phase 2Completed
- Sponsor
- Fudan University
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in breast cancer, sponsored by Fudan University. Started Sep 2020; status: completed.
02
Drugs
pucotenlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04508803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508803.